Nicholas Heathscott, MD
Family Medicine · Plant City, FLNPI 1104351626
Payments from drug & device makers
What this record shows
This record is dominated by grants: $10,000 of the $15,911 with a category attached, or 62.8%. Arthrex accounts for 63.6% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2020 at $10,033 and has fallen 84.3% since, to $1,575 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 289 payments — averaging $55.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$10K
- Novo Nordisk$988
- Lilly USA, LLC$728
- Pfizer$481
- AbbVie$451
- Boehringer Ingelheim$378
- plus $3K from 32 others
What the payments were for
- Grants$10,00063%
- Food & beverage$5,91137%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 2 | $10,125 |
| Novo Nordisk | 59 | $988 |
| Lilly USA, LLC | 40 | $728 |
| Pfizer | 27 | $481 |
| AbbVie | 23 | $451 |
| Boehringer Ingelheim | 18 | $378 |
| Amgen(2 entities) | 21 | $343 |
| AstraZeneca | 17 | $303 |
| Smith+Nephew | 2 | $268 |
| Exact Sciences | 13 | $248 |
| Bayer | 8 | $208 |
| GSK | 9 | $180 |
| Dexcom, Inc. | 5 | $176 |
| Zimmer Biomet | 2 | $169 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $144 |
| Abbott | 5 | $81 |
| Sumitomo Pharma America, Inc. | 4 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $76 |
| Corcept Therapeutics | 3 | $49 |
| Bioventus LLC | 1 | $45 |
| Azurity Pharmaceuticals, Inc. | 2 | $40 |
| Stryker | 1 | $29 |
| Astellas Pharma US Inc | 1 | $26 |
| MVP Orthopedics Inc | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Lucid Diagnostics Inc. | 1 | $23 |
| Shield Therapeutics Inc | 1 | $23 |
| Si-bone, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Nevro Corp. | 1 | $19 |
| Silk Road Medical, Inc. | 1 | $19 |
| Halozyme Inc | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VISIONAIRE$139
- Sports Medicine-None$136
- REGENETEN Shoulder$129
How this compares
$15,911 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 172 | $200,947 |
| EliquisApixaban | 81 | $89,485 |
| JardianceEmpagliflozin | 57 | $84,536 |
| MounjaroTirzepatide | 39 | $53,572 |
| TrulicityDulaglutide | 46 | $52,314 |
| FarxigaDapagliflozin Propanediol | 30 | $37,973 |
| XareltoRivaroxaban | 14 | $21,109 |
| EntrestoSacubitril/Valsartan | 14 | $17,098 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $10,221 |
| Novolog FlexpenInsulin Aspart | 32 | $7,896 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $7,198 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $6,970 |
| Gabapentin | 138 | $4,119 |
| Rosuvastatin Calcium | 304 | $2,869 |
| Varenicline Tartrate | 13 | $2,843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $988 | $200,947172 claims |
| Lilly USA, LLCMounjaro, Trulicity | $728 | $105,88685 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $378 | $94,75769 claims |
| PfizerEliquis | $481 | $89,48581 claims |
| AstraZenecaFarxiga, Symbicort | $303 | $44,94352 claims |
| Johnson & JohnsonXarelto | $20 | $21,10914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Plant City
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.